Genetic testing

American Kidney Fund Announces April 30 as the First Annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day

Retrieved on: 
Thursday, January 25, 2024

ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day .

Key Points: 
  • ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day .
  • Building on AKF’s educational campaign for the condition, AMKD Awareness Day aims to spread awareness of APOL1-mediated kidney disease (AMKD) , a spectrum of kidney diseases associated with variants (mutations) in the apolipoprotein L1 (APOL1) gene and linked to an increased risk for rapidly progressing kidney disease in people of Western and Central African descent.
  • People with two mutations are at higher risk of developing genetic forms of kidney disease such as focal segmental glomerulosclerosis (FSGS).
  • Additionally, AKF will provide resources and ways to engage and raise awareness of the important connection between APOL1 gene variants and kidney disease in the months ahead.

Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024

Retrieved on: 
Tuesday, January 23, 2024

Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).

Key Points: 
  • Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).
  • Baylor Genetics and partner Baylor College of Medicine have served as the sole sequencing core for UDN since its inception in 2014, providing WGS/WES testing, interpretation, validation and reporting for patients with rare genetic diseases.
  • The Harvard Gazette recently published one such story, noted in a Baylor Genetics blog on navigating the maze of undiagnosed diseases.
  • Learn more about PMWC through the conference website and visit the Baylor Genetics website to explore the company’s full spectrum of genetic testing capabilities.

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Retrieved on: 
Thursday, January 18, 2024

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Key Points: 
  • SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.
  • By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio.
  • Upon the closing of the acquisition on February 1, 2024, Myriad expects to operate TheraMap: Solid Tumor solely as Precise Tumor.
  • The financial terms of the deal were not disclosed but are not material to either Myriad or Intermountain Healthcare.

Gattaca Genomics Unveils State-of-the-Art Genetic Testing Services to Transform Family Planning

Retrieved on: 
Thursday, January 18, 2024

Fort Lauderdale, FL, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a pioneering next generation company innovating solutions for reproductive health, is set to revolutionize family planning with its advanced genetic testing services.

Key Points: 
  • Fort Lauderdale, FL, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a pioneering next generation company innovating solutions for reproductive health, is set to revolutionize family planning with its advanced genetic testing services.
  • Specializing in Preimplantation Genetic Testing (PGT), Gattaca Genomics employs state-of-the-art techniques to enhance pregnancy success rates, identify chromosomal abnormalities, and reduce the risk of genetic disorders.
  • Whole Genome Sequencing (WGS): Gattaca Genomics introduces a breakthrough in genetic testing with Whole Genome Sequencing, offering a comprehensive analysis of an individual's entire genome.
  • Gattaca Genomics invites prospective parents, healthcare providers, and clinicians to explore the possibilities that genetic testing can offer.

Newtopia Launches "GLP-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss Drugs

Retrieved on: 
Monday, January 29, 2024

Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years.

Key Points: 
  • Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years.
  • At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.
  • If the weight does not stay off, the expense of GLP-1s and related drugs is hard to justify.
  • But if Newtopia helps users sustain their weight loss, especially when they cycle off the drug protocol, payers, employers, and providers can begin to rationalize prescribing and funding greater access to these medications."

2024 Employee Benefit Plans: Focus on Costs, Mental health, Well-being

Retrieved on: 
Monday, January 29, 2024

36% ranked cost containment as the top priority—a 17% increase compared to January 2023.

Key Points: 
  • 36% ranked cost containment as the top priority—a 17% increase compared to January 2023.
  • Today's cost-conscious climate makes it especially important for advisors and customers to clarify priorities, said Mark Sylvia, President and CEO of Empire Life.
  • We definitely see an increased emphasis on making sure employees can come to work feeling better, feeling healthy, feeling connected."
  • According to Black, 72% of businesses surveyed had a specific strategy to support mental health and 30% were adopting the National Standard for Psychological Health and Safety.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

Industry-Disrupting Online Cannabis Seed Marketplace Launches in the United States

Retrieved on: 
Friday, January 26, 2024

CHICAGO, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Apiary Agriculture Inc. is thrilled to announce the launch of an innovative new cannabis marketplace, Trusted Source, built with powerful software from Arcadier, Pte. Ltd (Arcadier). The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.

Key Points: 
  • The most robust cannabis seed platform on the market opens online, utilizing technology developed by a global digital marketplace provider.
  • CHICAGO, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Apiary Agriculture Inc. is thrilled to announce the launch of an innovative new cannabis marketplace, Trusted Source, built with powerful software from Arcadier, Pte.
  • The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.
  • The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.

SOPHiA GENETICS Supports Genetic Testing in Brazil

Retrieved on: 
Thursday, January 25, 2024

BOSTON and ROLLE, Switzerland, Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS' technology to advance and streamline its genetic testing capabilities.

Key Points: 
  • The company will use SOPHiA GENETICS' technology to advance and streamline its genetic testing capabilities.
  • Bioma4me is a leader in Brazil in providing personalized medicine, supported by genetic analysis of each individual, offered at an affordable cost, with great precision and in the shortest possible time.
  • "We are thrilled to announce our collaboration with SOPHiA GENETICS, a leader in AI to further precision medicine.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Susan G. Komen® Pushing for Public Policies to Eliminate Disparities in Breast Care Access

Retrieved on: 
Thursday, January 25, 2024

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, is committed to making health care more affordable and accessible to all, by passing state and federal legislation in 2024 to remove barriers that prevent people from receiving the timely and high-quality breast care they need.

Key Points: 
  • Public policies that remove ob­­­­­­stacles, such as the cost of care and when and where care is available, would make an immediate difference in mortality rates.
  • In fact, about one-third of breast cancer deaths could be prevented if everyone received the high-quality care that exists today.
  • Breast imaging, the most effective tool at detecting breast cancers, is available to most people yet is not accessible to all.
  • "Komen is approaching breast cancer comprehensively through diverse public policy initiatives, aiming to minimize the number of breast cancer deaths," Guthrie added.